US Patent Issued for Compound that Delivers Taxotere Chemotherapy Directly into Tumors

US Patent Issued for Compound that Delivers Taxotere Chemotherapy Directly into Tumors
A U.S. patent has been issued for Rexahn Pharmaceuticals‘ RX-21101, a drug that allows the targeted delivery of the chemotherapy agent Taxotere (docetaxel) directly into tumor cells. This may improve the safety and effectiveness of Taxotere in a number of cancers, including prostate cancer. “We are pleased to expand our intellectual property covering our unique and

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *